Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported.
from Latest Science News -- ScienceDaily https://ift.tt/0LH9PVY
from Latest Science News -- ScienceDaily https://ift.tt/0LH9PVY
Comments
Post a Comment